INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16
O ver the last decade or two, studies on oncogenes and tumor suppressor genes have increasingly provided evidence that cancer develops from the activation of oncogenes and/or the loss or mutation of tumor suppressor genes. 1, 2 Based on this concept, new strategies have been developed rapidly as alternatives to conventional cancer therapy. One of them is cancer gene therapy, whereby insertion of various genes such as the tumor suppressor gene into tumor cells can either restore the normal function of a defective tumor suppressor gene or eliminate the abnormal function of an oncogene product. 3, 4 p16
INK4 is a tumor suppressor gene that was identified and cloned from studies of cell senescence 5 and cell cycle control. 6 It maps to the chromosome 9p21 region, 7 which is frequently deleted, mutated, or silenced by promoter methylation in many human tumors. 8 -10 The major transitions of the eukaryotic cell cycle are triggered by cyclin-dependent kinases (CDKs).
7 CDK4 regulates progression through the G 1 phase of the cell cycle. In normal cells, the retinoblastoma tumor suppressor gene (Rb) regulates cell proliferation by binding and sequestering transcription factors essential for progression to the S phase. These transcription factors are released at the late G 1 phase by phosphorylation of Rb, thereby allowing cells to enter the S phase. The main function of the CDK4-cyclin D complex is to phosphorylate Rb at late G 1 . 11 The p16 gene has been biochemically characterized as a protein that specifically binds to and inhibits CDK4 and functions as a negative cell-cycle regulator by controlling the activity of CDK4-cyclin D, leading to regulation of Rb phosphorylation. 12, 13 Because the loss of growth control is a common feature of malignant transformation, it is reasonable to hypothesize that deranged CDK inhibitors such as p16
INK4 will result in loss of cell growth control. There is now growing evidence that shows that restoration of the p16 INK4 gene in p16-depleted tumor cells significantly suppresses tumor growth in vitro and in vivo. 14 -16 Breast cancer is one of the most common malignancies in North American women, affecting as many as one in eight, and this type of cancer is responsible for as many as one in five cancer-related deaths in women. 17, 18 Aberrant p16
INK4 expression was reported in 30 -60% of breast cancer cell lines, 19 -21 but at a relatively lower frequency in primary breast tumors according to the polymerase chain reaction/single-strand conformation polymorphism method. 19, 20, 22, 23 However, in a recent study using more controllable immunohistochemical assays, Geradts and Wilson reported a high frequency (49%) of aberrant p16
INK4 expression in 104 archival breast tumors. 24 Their results indicate that aberrant p16
INK4 expression is much more frequent than was previously thought and may, in fact, be one of the most common abnormalities in human breast cancer.
Recombinant adenovirus has facilitated gene transfer into a variety of cell types, both benign and malignant. 25, 26 Adenoviral vectors have a broad host and cell range and high levels of gene expression. The ability to produce large quantities of purified adenovirus with relative ease makes this system very attractive for clinical use. Adenovirus-mediated p16
INK4 gene transfer as a cancer gene therapy approach has been investigated in several types of human malignancies with p16
INK4 deletion, including non-small cell lung cancer, esophageal carcinomas, gliomas, and prostate cancer. 14 -16,27 In the present study, we evaluated the relative antitumoral activity of the p16
INK4 tumor suppressor gene in p16 INK4 -deleted breast cancer cell lines in vitro and in vivo by using adenovirus-mediated gene transfer.
MATERIALS AND METHODS

Cell lines, antibodies (Abs), and animals
Various human cell lines were used in this study. These include four breast carcinoma cell lines (MCF-7, MDA-MB-231, BT-549, and T-47D), a cervical epithelioid carcinoma cell line (HeLa), and a lymphoblastic leukemia cell line (MOLT-4). All of these cell lines were obtained from the American Type Culture Collection (Manassas, Va) and maintained in RPMI 1650 medium plus 10% fetal calf sera. The human embryonic kidney cell line 293, transformed with AdV5 E1, was obtained from Microbix Biosystems (Toronto, Ontario, Canada) and maintained in Eagle's minimum essential medium plus 10% fetal calf serum. Various mouse monoclonal Abs recognizing p16 INK4 , Rb, proliferating cell nuclear antigen (PCNA), and pan-keratin (AE1/AE3/PCK26) were purchased from PharMingen Canada (Mississauga, Ontario, Canada). BALB/c nu/nu mice were purchased from Charles River (Montreal, Quebec, Canada) and maintained in our pathogen-free animal facility at the Saskatoon Cancer Center.
Recombinant adenoviruses
Three recombinant adenoviruses were used in this study, namely AdV-LacZ, AdV-p16, and AdV-pLpA. The adenovirus AdV-LacZ contains the Escherichia coli ␤-galactosidase (␤-gal) marker gene under the transcriptional control of the human cytomegalovirus promoter. The adenoviral vector pLpA-p16 was constructed in our laboratory by insertion of the p16 INK4 cDNA into the adenoviral expression vector pLpA. 28 The recombinant adenoviruses AdV-p16 and AdV-pLpA were produced by cotransfection of pLpA-p16 or pLpA DNA with pJM17 DNA in 293 cells. 28 Subsequent homologous recombination between the two plasmids (pLpA-p16 or pLpA and pJM17) resulted in the clones of adenoviruses AdV-p16 and AdV-pLpA. Viral seed stocks were then obtained by amplification in 293 cells. Working stocks of the virus were obtained by harvesting 293 cells at 36 hours postinfection with appropriate seed stock. The cell pellet was lysed by three freeze-thaw cycles. Adenovirus was then purified by two rounds of CsCl ultracentrifugation. Purified virus was mixed with 10% glycerol and dialyzed twice against 500 mL of dialysis buffer containing 10 mM tris(hydroxymethyl)aminomethane/HCl (pH 7.5), 1 mM MgCl 2 , and 10% glycerol at 4°C for 6 hours. Purified virus was aliquoted and stored at Ϫ80°C until use.
Western blot analysis
Tumor cells from one 10-cm dish with or without adenoviral infection were scraped off using a rubber policeman with 300 L of extraction buffer containing 125 mM tris(hydroxymethyl)aminomethane, 0.05% sodium dodecyl sulfate, and 10% ␤-mercaptoethanol. Cell extracts were harvested. To remove cellular debris, cell extracts were centrifuged at 1000 ϫ g for 5 minutes. The supernatant containing protein samples (30 g) was electrophoresed through 15% gels and transferred onto nitrocellulose papers; blots were incubated with various mouse monoclonal Abs (1 g/mL) recognizing p16
INK4 , Rb, and PCNA molecules as controls, respectively. For detection of Rb protein, protein samples were electrophoresed through 8% gels. Blots were washed with phosphate-buffered saline (PBS) containing 0.1% Tween 20 and further incubated with horseradish peroxidase-conjugated goat anti-mouse Ab. Detection was accomplished by using enhanced chemiluminescence reagent according to the manufacturer's protocol (New England Nuclear Life Science Products, Boston, Mass).
Infection of tumor cells in vitro with AdV-LacZ adenovirus
The in vitro ability of adenovirus AdV-LacZ to infect various tumor cell lines was assessed. Briefly, four breast cancer cell lines were seeded onto a triplicate of 96-well tissue culture plates at a concentration of 0. 
Immunohistochemical study
The breast cancer cell lines MCF-7, MDA-MB-231, and T-47D (1 ϫ 10 5 cells in a 60-mm dish) were infected with AdV-p16 at an MOI of 50 PFU/cell, except for MCF-7, which was infected at an MOI of 150 PFU/cell. Tumor cells were harvested at 1 day postinfection. Cell pellets were fixed in 10% neutralbuffered formalin and routinely embedded in paraffin. Sections were deparaffinized in xylene and rehydrated in graded alcohols. Endogenous peroxidase activity was quenched by incubating the slides with 0.3% hydrogen peroxide in methanol for 15 minutes followed by three PBS rinses. The slides were incubated with normal rabbit sera to reduce any nonspecific staining. For examination of p16 expression, the slides were incubated with mouse anti-p16 Ab and anti-pan-keratin Ab as a control at 10 g/mL overnight at 4°C. The slides were washed and subsequently incubated with biotinylated goat anti-mouse immunoglobulin G Ab at 10 g/mL. For examination of apoptosis, an apoptosis (APO)-bromodeoxyuridine (BRDU) kit (Phoenix Flow Systems, San Diego, Calif) was used. Briefly, the slides were incubated with the DNA labeling solution containing the terminal deoxynucleotidyl transferase enzyme and bromo (Br)-deoxyuridine triphosphate (dUTP) according to the manufacturer's protocol. The slides were washed and then incubated with the Ab solution containing the biotin-antiBr-dUTP Ab. These slides were washed three times with PBS and then incubated with avidin-biotin-peroxidase complex reagents for 30 minutes. The peroxidase activity was developed with freshly prepared 0.06% 3Ј,3Ј-diaminobenzidine containing 0.1% hydrogen peroxide. Hematoxylin was used as the counterstain.
In vitro cell growth and flow cytometry analysis after AdV-p16 infection
To study the inhibition of cell growth in vitro, four breast cancer cell lines (5 ϫ 10 5 cells in a 60-mm dish) were infected with AdV-p16 and AdV-pLpA (as a control) as described above. Culture medium was used for mock infections. Triplicate dishes of each treatment were counted daily for 5 days. The cell viability was determined by trypan blue exclusion. To measure DNA histograms, tumor cells were harvested 3 days after viral infection, resuspended in ice-cold PBS buffer containing 0.3 mM ethylenediaminetetraacetic acid, and fixed by the gradual addition of ice-cold 100% ethanol to a final concentration of 80%. The fixed cells were kept at 4°C for 3 days, pelleted, and resuspended in 1 mL of the above buffer containing 5 g/mL propidium iodine (Sigma, St. Louis, Mo) and 10 g/mL ribonuclease. The samples were incubated at 37°C for 30 minutes and then analyzed using a Coulter Epics XL flow cytometer (Coulter, Burlington, Ontario, Canada). The Multiplus AV software package from Phoenix Flow Systems was used for data analysis. Mean peak fluorescence was determined for each histogram.
Tumorigenicity assay
MDA-MB-231 cells were infected with AdV-p16 and AdVpLpA virus, respectively, at an MOI of 150. An equal amount of cells was treated with medium as a mock infection. At 2 hours postinfection, infected tumor cells (2 ϫ 10 6 cells in 50 L of Metrigel per mouse) were injected subcutaneously (s.c.) into the right thigh of each nude mouse. Metrigel, which contains a mixture of laminin, collagen IV, heparan sulfate, and entactin, was purchased from Becton Dickinson Labware (Bedford, Mass). It has been reported that Metrigel was able to significantly enhance human breast tumor growth in nude mice, although the tumor growth rate was not 100%. 29 Mice were sacrificed at 2 weeks after tumor inoculation. Tumors were removed for histological analysis.
Intratumoral (i.t.) vaccination with recombinant adenoviruses
MDA-MB-231 tumor cells (2 ϫ 10 6 cells in 50 L of Metrigel per mouse) were injected s.c. into the right thighs of mice. When tumors became palpable (ϳ3 mm in diameter), mice were injected i.t. with 2 ϫ 10 9 PFU of adenoviruses AdV-p16 and AdV-pLpA, respectively. The injection was repeated at day 4. Tumor growth or regression was monitored by measuring tumor diameter using a caliper. Mice were sacrificed at 2 weeks after the initial adenoviral vaccination, and tumors were removed, weighed, and examined histologically.
RESULTS
Expression of endogenous p16
INK4 and Rb
The MCF-7 and MDA-MB-231 cell lines had homozygously deleted p16 INK4 genes, 20 whereas the T-47D cell line did not express p16 INK4 protein by DNA methylation. 30 All three of the cell lines have a wild-type (wt) Rb gene. The BT-549 cell line, which was selected to act as a control, has a wt p16
INK4 gene and a mutated Rb gene. 30 To confirm the above information, a Western blotting analysis was performed. As shown in Figure 1A  (lanes b, c, and d) , the MCF-7, MDA-MB-231, and T-47D cell lines showed endogenous expression of Rb but not p16
INK4 gene, whereas the BT-549 cell line ( Fig  1A, lane e) showed endogenous expression of p16
INK4
but not Rb gene. In this experiment, the protein extracts of HeLa and MOLT-4 cell lines (Fig 1A, lane a) were used as the positive controls for p16 INK4 and Rb molecules, respectively, and the mouse anti-PCNA Ab was used as a control for quantitation of sample protein of each cell line.
Efficiency of adenoviral infection in breast cancer cells
The infectivity of AdV-LacZ in vitro on tumor cells was determined by measuring the percentage of blue cells after cytochemical staining with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside at 1 day postinfection. A dosedependent response was noted in each of the cell lines tested. Most of the cell lines (MDA-MB-231, T-47D, BT-549, and MCR-5) attained their maximal infectivity (94%, 90%, 81%, and 82%, respectively) at an MOI of 50. The maximal infectivity for MCF-7 was 83% at an MOI of 150. Control cells not exposed to AdV-LacZ did not exhibit any intrinsic ␤-gal activity or false-positive staining.
Expression of exogenous p16 protein in human breast cancer cells
The strong cytomegalovirus promoter was used to drive p16 INK4 expression to obtain a high level of expression of this gene. Most of the tumor cell lines were infected with AdV-p16 or AdV-pLpA at an MOI of 50 in the subsequent experiments, except for the MCF-7 cell line, which was infected at an MOI of 150. As shown in Figure 1B  (lanes b, c, and d) , high levels of exogenous p16
INK4
protein expression were achieved in the MCF-7, MDA-MB-231, and T-47D cells in Western blots 3 days after AdV-p16 infection. In this experiment, the mouse anti-PCNA Ab was used as a control for quantitation of sample protein. In contrast, cells infected with a control adenovirus, AdV-pLpA, had no detectable increase in the level of p16 expression compared with the level of a control protein PCNA (data not shown). To further visualize the exogenous expression of p16
INK4 gene, an immunohistochemical study was performed using the mouse anti-p16 Ab. Three breast cancer cell lines (MCF-7, MDA-MB-231, and T-47D) were infected with AdV-p16. A large amount of exogenous p16 INK4 expression was detected in both the nuclei and cytoplasm of AdV-p16-infected MDA-MB-231 cells (Fig 2A) . In this experiment, the mouse anti-keratin Ab, which detects the cytoplasmic keratins, was used as a control to confirm the quality of this immunohistochemical method (Fig 2B) . No endogenous p16
INK4 expression was seen in this cell line (Fig 2C) . The strong and diffuse cytoplasmic expression of p16 INK4 has also been seen in some human tumor tissues, such as breast and cervical cancers. 31, 32 The expression of exogenous p16
INK4 was also seen in AdV-p16-infected MCF-7 and T-47D cell lines (data not shown). Subsequently, the effect of the introduced p16
INK4 protein on the tumor cell lines was examined in the following assays.
Effect of p16
INK4 protein on breast cancer cell growth Four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D, and BT-549) were infected with AdV-p16. Triplicate sets of the infected and mock-infected cells were counted every day for 6 days, and the mean cell number for each day was calculated. As shown in Figure 3 , the cell growth curves of four tumor cell lines were similar. However, three cell lines (MCF-7, MDA-MB-231, and T-47D) with aberrant p16 INK4 and wt Rb gene exhibited marked growth inhibition after AdV-p16 infection, whereas the cell line (BT-549) with wt p16
INK4 and mutated Rb gene did not show any growth inhibition. All controls representing cell lines with mock infection or infected with AdV-pLpA did not show any significant growth inhibition. These results suggest that tumor cells expressing exogenous p16
INK4 have an altered exponential growth phase. At 6 days after infection with AdVp16, the growth rates of the AdV-p16-infected MCF-7, MDA-MB-231, and T-47D cells were inhibited by 94%, 98%, and 90%, respectively, compared with the growth rates of the AdV-pLpA-infected cells. However, the growth rate of BT-549 with endogenous p16
INK4 infected with AdV-p16 was not inhibited at all.
Cell cycle arrest and apoptosis mediated by AdV-p16 At 3 days after AdV-p16 infection, cells were harvested for cell cycle analysis by flow cytometry. As shown in Figure 4 , AdV-p16-mediated expression of p16 INK4 protein significantly increased 19%, 14%, and 18% of cells in the G 1 phase in the p16 INK4 -deleted breast cancer cell lines MCF-7, MDA-MB-231, and T-47D, respectively, suggesting the induction of G 1 phase arrest. In addition, two cell lines (MDA-MB-231 and T-47D) also showed 60% and 36% apoptosis that displayed subdiploidy peaks in DNA histograms. 33 In contrast, no G 1 phase arrest and apoptosis were seen in p16 INK4 proteinpositive BT-549 with mutated Rb gene. The induced apoptosis was further confirmed in a histochemical study by using the APO-BRDU kit. As shown in Figure 5 , scattered apoptosis (arrows) was seen in MDA-MB-231 tumor cells infected with AdV-p16.
Inhibition of tumorigenicity mediated by AdV-p16
To determine whether the exogenous p16
INK4 expression affects their tumorigenicity, BALB/c nu/nu mice were inoculated with MDA-MB-231 tumor cells with and without infection of AdV-p16. As shown in Table 1 , AdV-p16-treated tumor cells completely suppressed tumor growth in vivo, whereas 70% and 80% of mice that received AdV-pLpA-and medium-treated MDA-MB-231 cells developed tumors, respectively. Our results demonstrated that the tumorigenicity of breast tumor cells was completely inhibited by prior treatment with AdV-p16, indicating that the p16 INK4 protein may have therapeutic efficacy. The therapeutic potential for AdVp16 was further examined in a BALB/c nu/nu mouse tumor model. As shown in Figure 6 and Table 2 , the growth of MDA-MB-231 tumors with treatment of AdV-p16 was significantly inhibited compared with that of tumors that were treated with AdV-pLpA and PBS. The mean weight of AdV-p16-treated tumors was 0.21 g, which is significantly smaller than that of AdV-pLpAand PBS-treated tumors (1.02 g and 1.23 g, respectively) (P Ͻ .01). In addition, AdV-pLpA treatment alone has also shown some effect on tumor growth inhibition in vivo, although this effect is much milder. As further shown in Figure 7 , the AdV-p16-treated tumors showed multiple large areas of necrosis, possibly due to apoptosis induced by exogenous expression of p16
INK4
, whereas the AdV-pLpA-treated tumors only displayed small focal areas of necrosis. 9 PFU AdV-p16 (E), 2 ϫ 10 9 PFU AdV-pLpA (OE), or PBS (F), respectively. The injection was repeated once at day 4. Tumor growth or regression was monitored by measuring tumor diameter using a caliper. 
DISCUSSION
To investigate the efficacy of breast cancer therapy mediated by adenovirus-mediated p16
INK4 gene transfer, four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D, and BT-549) were selected in this study. These include three tumor cell lines (MCF-7, MDA-MB-231, and T-47D) with a deficiency in p16
INK4 expression and one tumor cell line (BT-549) with wt p16
INK4 but mutated Rb as a control. The aforementioned four cell lines were infected with AdV-p16. Our data showed that they all expressed the exogenous p16
INK4 after infection, and that the induced expression of p16 INK4 significantly inhibited their growth rates in vitro. It is known that the p16 INK4 protein is able to inhibit the activity of CDK4, thereby blocking the entry of proliferating cells from G 1 to S phase. 34 The mechanism involved in the inhibition of the growth rate mediated by AdV-p16 was examined. The data that we obtained from fluorescence-activated cell sorter analysis showed that expression of exogenous p16
INK4 blocked tumor cell entry into the S phase of the cell cycle and induced cell apoptosis. The induced apoptosis was further confirmed by immunohistochemical analysis using the APO-BRDU kit. In contrast, no G 1 phase arrest and apoptosis were seen in the BT-549 cell line with wt p16
INK4 and the mutated Rb gene. These results indicate that wt endogenous Rb expression is a critical determinant of p16
INK4 -mediated cell cycle arrest and cytotoxicity; they also suggest that the p16
INK4
protein not only suppresses the growth of tumor cells by mediating G 1 arrest but also induces cell death by apoptosis in tumor cell lines that have wt Rb but do not in diameter) , each mouse in groups I and II was injected i.t. with 2 ϫ 10 9 PFU of AdV-p16 and AdV-pLpA, respectively. In the control group, each tumor was injected with PBS. Two weeks after injection of AdV-p16, tumors were removed and weighed.
†The mean tumor weight represents the total tumor weight from each group of mice divided by 8.
‡The value in group I is significantly different (P Ͻ .01) from that in group II and in controls (Student's t test).
